AG53-1
Actuarial Guideline LIII
APPLICATION OF THE VALUATION MANUAL FOR TESTING THE
ADEQUACY OF LIFE INSURER RESERVES
Background
The NAIC Valuation Manual (VM-30) contains actuarial opinion and supporting actuarial memorandum
requirements, including requirements for asset adequacy analysis. Regulators have observed a lack of
uniform practice in the implementation of asset adequacy analysis. The variety of practice in incorporating
the risk of complex assets into testing does not provide regulators comfort as to reserve adequacy. Examples
of complex assets are structured securities, including asset-backed securities and collateralized loan
obligations, as well as assets originated by the company or affiliated or contracted entity. An initial increase
of this activity has been noted in support of general account annuity blocks; however, recent activity was
noted in other life insurer blocks.
This Guideline is intended to provide uniform guidance and clarification of requirements for the appropriate
support of certain assumptions for asset adequacy analysis performed by life insurers. In particular, this
Guideline:
(1) Helps identify reserve adequacy and claims-paying ability in moderately adverse
conditions, including conditions negatively impacting cash flows from complex assets.
(2) Clarifies elements to consider in establishing margins on asset-related assumptions.
(3) Ensures recognition that higher expected gross returns from assets are, to some extent,
associated with higher risk, and that assumptions fit reasonably within the risk-return
spectrum.
(4) Requires sensitivity testing regarding complex assets supporting life insurer business.
(5) Identifies expectations in practice regarding the valuation of complex assets within asset
adequacy analysis.
(6) Reflects that while complex assets tend to have higher uncertainty regarding timing and
amount of cash flows than more traditional investments, because complex assets are
difficult to classify, and the regulatory concern is regarding the projected net yields and
cash flows from those assets, the focus of the analysis requirements will be on assets
categorized as high-yielding.
(7) Requires additional documentation of investment fee income relationships with affiliated
entities or entities close to the company.
Text
1. Effective Date
This Guideline shall be effective for asset adequacy analysis of the reserves reported in the
December 31, 2022, Annual Statement and for the asset adequacy analysis of the reserves reported
in all subsequent Annual Statements.
AG LIII Appendix C
AG53-2
Guidance Note: It is anticipated that the requirements contained in this Guideline will be
incorporated into VM-30 at a future date, effective for a future valuation year. Requirements in the
Guideline will cease to apply to annual statutory financial statements when the corresponding or
replacement VM-30 requirements become effective.
2. Scope
This Guideline shall apply to all life insurers with:
A. Over $5 billion of general account actuarial reserves (from Exhibits 5, 6, 7 and 8 of the
annual statement) and non-unitized separate account assets, or
B. Over $100 million of general account actuarial reserves (from Exhibits 5, 6, 7 and 8 of the
annual statement) and non-unitized separate account assets and over 5% of supporting assets
(selected for asset adequacy analysis) in the category of Projected High Net Yield Assets,
as defined in Section 3.F.
Actuarial reserve amounts are included in the amounts in A and B whether directly written or
assumed through reinsurance and are determined before any reinsurance ceded credit.
This Guideline applies to assets supporting liabilities tested in the asset adequacy analysis except it
does not apply to unitized separate account assets or policy/contract loans.
3. Definitions
A. Equity-Like Instruments Assets that include the following:
i. Any assets that, for purposes of risk-based capital C-1 reporting, are in the category
of common stock, i.e., have a 30% or higher risk-based capital charge.
ii. Any assets that are captured on Schedule A or Schedule BA of the annual
statement.
iii. Bond funds.
B. Fair Value The price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date, consistent
with methodology of fair value, as reported in the Annual Statement.
C. Net Market Spread For each asset grouping, shall mean the spread over comparable
Treasury bonds that equates the fair value as of the valuation date with modeled cash flows,
less the default assumption used in asset adequacy analysis.
Market conventions and other approximations are acceptable for the purposes of this definition.
D. Investment Grade Net Spread Benchmark The applicable spread found in Appendix I
using the weighted average life (WAL) of the associated non-equity-like instrument.
E. Guideline Excess Spread The net spread derived by subtracting the Investment Grade Net
Spread Benchmark from the Net Market Spread for non-equity-like instruments.
Investment expenses shall be excluded from this calculation.
F. Projected High Net Yield Assets Currently held or reinvestment assets that are either:
Appendix C AG LIII
AG53-3
i. An equity-like instrument assumed to have higher value at projection year 10 or
later than under an assumption of annual total returns, before the deduction of
investment expenses, of 4% for the first 10 projection years after the valuation date
followed by 5% for projection year 11 and after. Aggregation shall be done at a
level of granularity that is consistent with or more granular than how the assets are
grouped, i.e., compressed, in the asset adequacy analysis model, or
ii. Assets other than equity-like instruments where the assumed Guideline Excess
Spread is higher than zero. In addition:
(a) Aggregation of the comparison between the assumed Net Market Spread
from each asset and the Investment Grade Net Spread Benchmark shall be
done at a level of granularity that is consistent with or more granular than
how the assets are grouped, i.e., compressed, in the asset adequacy analysis
model.
(b) For applicable assets that do not have an explicit WAL or term to maturity,
the appointed actuary shall disclose the method used to determine the
appropriate WAL used for comparing to the Investment Grade Net Spread
Benchmark.
(c) For purposes of the comparison between the assumed Net Market Spread
from each asset and the Investment Grade Net Spread Benchmark,
investment expenses shall be excluded.
iii. The following asset types can be excluded from the scope of requirements in
sections 4.A.ii. through 5.:
(a) Cash or cash equivalents
(b) Treasuries and agency bonds
(c) Public non-convertible, fixed-rate corporate bonds with no or immaterial
callability
4. Asset Adequacy Considerations and Documentation Expectations
A. Net Return and Risk Documentation
i. For all assets, either currently held or in assumed reinvestments, provide:
(a) Identification of the assumed gross asset yield and the key components (for
example, default and investment expenses) deducted to arrive at the
assumed net asset yield.
(b) Explanation of any future reinvestment strategy assumptions that
materially differ from current practices.
ii. For projected high net yield assets, either currently held or in assumed
reinvestments, provide:
(a) A detailed explanation describing the relationship between the expected
gross returns from these assets and the risk. It shall also include, for the
aspect of any higher expected gross returns not assumed to be associated
AG LIII Appendix C
AG53-4
with higher risk, an explanation of how overperforming assets with
expected returns lying outside the risk-return spectrum can be assumed to
persist and be available for reinvestments throughout the projection period
in moderately adverse conditions.
(b) Commentary on how assumptions on assets with risk factors leading to
substantial volatility of returns, as identified through sensitivity testing or
other means, contain an appropriate margin to reflect the uncertainty in the
timing and amounts of asset cash flows.
(c) Identification of the extent to which projected high net yield assets are
supporting major product categories, e.g., individual fixed annuities and
pension risk transfers.
(d) Explanation of rationale for materially changing or not changing complex-
asset-based assumptions from the prior year’s analysis.
B. Model Rigor Where significant risks associated with complex, projected high net yield
assets are not adequately captured with traditional modeling techniques, more rigorous
modeling of those risks should occur.
i. Where necessary to adequately reflect the risk:
(a) Multi-scenario testing of those risks specific to complex assets should be
performed. For example, investments that may provide a higher expected
return in part due to limited information, niche skill sets, or other factors
may require unique scenarios (for instance to adequately capture credit or
liquidity risk) to fully encompass potential sources of loss.
(b) Asset cash flows should be appropriately projected to reflect anticipated
liquidity under adverse conditions. If such model aspects are not
developed, sufficient additional conservatism to reflect this risk shall be
applied.
(c) To the extent that the process for modeling or otherwise evaluating the
risks is complex, and the potential for disconnect between reality and
modeling increases, an additional margin to assumption(s) should be
applied. Any such margin shall be applied in the direction of asset
adequacy analysis results being less favorable.
(d) The full distribution of risk associated with complex assets should be
considered.
ii. An appointed actuary may use simplifications, approximations, and modeling
efficiency techniques if the appointed actuary can demonstrate that the use of such
techniques does not make asset adequacy analysis results more favorable. These
techniques may be less appropriate if the amount of complex, high-yielding assets
becomes a higher percentage of total assets.
Guidance Note: Actuarial Standards of Practice (ASOPs), including ASOP No. 7
and No. 56 contain additional guidance on the use of models in the analysis of cash
flows.
Appendix C AG LIII
AG53-5
C. Fair Value Determination In asset adequacy analysis, when an asset is projected to be
available for sale, a fair value of that asset is established, based on the projected market
conditions. Fair value should only be determined internally (by the insurance or investment
management company) when the market-based value of the asset or similar asset cannot
be obtained or expected to be obtained in a projected scenario.
i. When the fair value of a material portion of supporting assets is determined
internally, the actuarial memorandum shall contain a step-by-step description of
the approach used to calculate the fair value of such assets.
ii. Provide the total fair value of assets that have values determined internally.
iii. When the fair value of a material portion of assets is determined internally, a
sensitivity test should be performed (and the impact on asset adequacy analysis
results presented) assuming a haircut to internally derived fair values that the
appointed actuary deems reasonable given the commensurate level of anticipated
uncertainty.
D. Non-Publicly Traded Assets For non-publicly traded assets originated by the company,
within the company’s group, or within an entity closely tied to a company’s group
(inclusive of the company's investment manager), provide the following:
i. Documentation of practices to help ensure accurate valuation of those assets.
ii. The total fair value of such assets.
iii. To the extent the contractual agreement affects the investment income revenue
streams included in the asset adequacy analysis, disclose in detail applicable
contractual agreements and revenue sharing, e.g., performance fees, between the
entity responsible for providing investment or other types of services and the
insurer.
Also, assumed net cash flows from assets should be net of all explicit or implicit fees or
expenses, such as origination fees, as well as reflective of other asset-related risks including
credit risk, illiquidity risk, and other market risks.
E. Investments Expenses (Fees) Assumed investment expenses, whether paid to an external
asset manager or to internal investment management staff, as well as additional expenses
that are directly attributable to the specific investments, should be commensurate with the
expected expenses in light of the complexity of the assets.
F. Reinsurance Modeling Related to reinsurance, relevant communications and disclosures,
for instance commentary on collectability and counterparty risk, should be presented in the
memorandum.
Guidance Note: Section 4.F is consistent with the standard laid out in ASOP No. 11
Reinsurance Involving Life Insurance, Annuities, or Health Benefit Plans in Financial
Reports.
G. Borrowing Please identify if any borrowing is modeled besides to address very short-term
liquidity needs. Also, verify borrowing and reinvestment rates to ensure that projections
are not materially benefiting from arbitrage advantages.
AG LIII Appendix C
AG53-6
5. Sensitivity Tests and Attribution Analysis related to Assumptions on Projected High Net Yield
Assets
A. Sensitivity Testing
i. Perform and disclose, separately for (a) and (b), the asset adequacy analysis results
from the following sensitivity tests:
(a) For reinvestment assets other than equity-like instruments, assume the Net
Market Spreads (before deduction of investment expenses) for Projected
High Net Yield Assets do not exceed the Investment Grade Net Spread
Benchmark and apply the test to a baseline of a level Treasury rate
scenario.
For the purposes of limiting the Net Market Spreads at the Investment
Grade Net Spread Benchmark, Projected High Net Yield Assets may be
aggregated together but shall not include any assets that are not Projected
High Net Yield Assets.
(b) For reinvestment assets that are equity-like instruments, assume annual
total returns, before the deduction of investment expenses, of 4% for the
first 10 projection years after the valuation date followed by 5% for
projection year 11 and after.
ii. Strict technical compliance for each asset may not be practical for reasons such as
model limitations. Professional judgment should be applied to produce sensitivity
testing results that are consistent with the spirit of the test. A variety of alternative
methods may be acceptable. Appropriate explanation and justification should be
provided for the method that was employed.
iii. Sensitivity testing for the purpose of this Guideline does not reflect commentary
on moderately adverse conditions, but the volatility and impact demonstrated from
the testing should be contemplated in Section 4.A.ii.(b) considerations.
B. For projected high net yield assets for non-equity-like instruments, either currently held or
in assumed reinvestments, perform and disclose the following attribution analysis steps at
the asset type level associated with the templates in Section 6:
i. State the assumed Guideline Excess Spread.
ii. Estimate the proportion of the Guideline Excess Spread attributable to the
following factors:
(a) Credit risk
(b) Illiquidity risk
(c) Deviations of current spreads from long-term spreads defined in Appendix
1
(d) Volatility and other risks (identify and describe these risks in detail)
Appendix C AG LIII
AG53-7
iii. Provide commentary on the results of Section 5.B.ii. Also, where judgment is
applied, provide supporting rationale of how the expected return in excess of the
Investment Grade Net Spread Benchmark is estimated.
Guidance Note: A best-efforts approach is expected for the year-end 2022
attribution analysis.
6. Reporting, Review, and Templates
Guidance Note: The NAIC Valuation Analysis (E) Working Group (VAWG) shall serve as a
resource in the targeted review of asset adequacy analysis related to modeling of business supported
with projected high net yield assets. VAWG shall provide periodic reports identifying outliers and
concerns regarding the analysis to help inform regulators on the effectiveness of this Guideline in
meeting the seven objectives stated in the Background section.
A. The documentation, sensitivity test results, and attribution analysis referenced above are to
be incorporated as a separate, easily identifiable section of the actuarial memorandum
required by VM-30 or as a standalone document, with a due date of April 1 following the
applicable valuation date. The domiciliary commissioner may approve a later due date for
companies seeking a hardship extension. The separate section or standalone document shall
be available to other state insurance commissioners in which the company is licensed upon
request to the company. The confidentiality and information provisions in state adoptions
of NAIC Model 820 regarding the actuarial memorandum are applicable to the separate
section or standalone document required by this Guideline.
B. The following sample templates adopted by the Life Actuarial (A) Task Force (LATF) are
available on the LATF web page (https://content.naic.org/cmte_a_latf.htm) under the
“Documents” tab:
i. Asset summary
ii. Components of net asset yield for various asset classes, with separate tables to be
provided for initial assets and reinvestment assets
iii. Sensitivity test aspects for projected high net yield assets that are fixed-income
iv. Sensitivity test results for projected high net yield assets
v. Attribution analysis, with separate tables to be provided for initial assets and
reinvestment assets for projected high net yield assets
AG LIII Appendix C
AG53-8
Appendix I Investment Grade Net Spread Benchmark
WAL (Weighted Avg Life)
Investment Grade Net Spread Benchmark
(in bps)
1-10 170
11-20 175
21-30 185